Blair William & CO Poseida Therapeutics, Inc. Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Poseida Therapeutics, Inc. stock. As of the latest transaction made, Blair William & CO holds 1,112,140 shares of PSTX stock, worth $3.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,112,140

Previous 1,101,325 0.98%

Holding current value

$3.18 Million

Previous $3.22 Million 1.09%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.7 - $4.04 $29,200 - $43,692	10,815 Added 0.98%	1,112,140 $3.18 Million
Q2 2024 Aug 12, 2024	BUY	$2.0 - $3.46 $272,546 - $471,504	136,273 Added 14.12%	1,101,325 $3.22 Million
Q1 2024 May 09, 2024	BUY	$2.76 - $4.13 $779,175 - $1.17 Million	282,310 Added 41.35%	965,052 $3.08 Million
Q4 2023 Feb 12, 2024	SELL	$1.83 - $3.51 $105,971 - $203,257	-57,908 Reduced 7.82%	682,742 $2.29 Million
Q3 2023 Nov 09, 2023	BUY	$1.62 - $2.79 $278,494 - $479,628	171,910 Added 30.23%	740,650 $1.76 Million
Q2 2023 Aug 11, 2023	BUY	$1.66 - $3.4 $887,099 - $1.82 Million	534,397 Added 1556.06%	568,740 $1 Million
Q1 2023 May 12, 2023	BUY	$3.08 - $8.73 $46,816 - $132,696	15,200 Added 79.4%	34,343 $105,000
Q4 2022 Feb 10, 2023	BUY	$3.33 - $6.38 $4,995 - $9,570	1,500 Added 8.5%	19,143 $101,000
Q3 2022 Nov 09, 2022	SELL	$2.43 - $4.51 $74,780 - $138,790	-30,774 Reduced 63.56%	17,643 $62,000
Q2 2022 Aug 10, 2022	BUY	$1.87 - $5.0 $5,984 - $16,000	3,200 Added 7.08%	48,417 $125,000
Q1 2022 May 13, 2022	SELL	$3.22 - $7.04 $12,062 - $26,371	-3,746 Reduced 7.65%	45,217 $203,000
Q4 2021 Feb 14, 2022	BUY	$6.23 - $7.6 $305,039 - $372,118	48,963 New	48,963 $333,000

Others Institutions Holding PSTX

# of Institutions

Shares Held

38.5M

Call Options Held

377K

Put Options Held

22.2K

View Full List

About Poseida Therapeutics, Inc.

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $245M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

More about PSTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account